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Chemotherapy-induced mitochondrial DNA (mtDNA) alterations
are well known in patients treated for viral infections with
nucleoside analogue reverse transcriptase inhibitors.1 It is also
hypothesized that certain chemotherapeutic agents for treatment
of cancer may cause mtDNA mutations in vitro.2,3 A study by
Wardell et al. reported mtDNA mutations after chemotherapy and
irradiation several years after the end of therapy. Although an
increase in mtDNA mutations was observed in this study, the level
of heteroplasmy (a mixture of mutated and normal mtDNA
molecules in one cell) was usually below 2%.4 The mitochondrion
contains multiple copies of DNA molecules per cell; therefore, it is
unlikely that random mutations induced by cytotoxic agents
would affect a high number of genome copies. Accordingly,
therapy-induced mutations were present at a low level.4
Recently, Carew et al.5 reported a high mtDNA mutation rate
in leukocytes of patients with chronic lymphatic leukemia (CLL)
after chemotherapy. In this study, the mtDNA sequences of
primary CLL cells were compared to the Cambridge reference
sequence. As expected, all patients displayed a variety of
homoplasmic differences to the reference sequence of the
mtDNA. No difference in the frequency of homoplasmic
mutations was observed in the untreated and treated group.
However, CLL cells with prior chemotherapy had a significant
higher frequency of heteroplasmic mutations than those of
untreated individuals.5 In all cases, a high level of heteroplasmy
between 30 and 70% was detected.
A similar observation was made in our laboratory in a patient
with a relapse of acute lymphoblastic leukemia (ALL) (male, age
6 years). The mutation screening of the complete mtDNA
revealed 19 acquired somatic heteroplasmies in peripheral
blood mononucleoar cells (PBMC) 4 weeks after the onset of
therapy (data not shown). The therapy regimen (Berlin–
Frankfurt–Mu¨nster (ALL-BFM) protocol) was identical to the
one in the other 11 patients treated for ALL in our hospital,
where we did not detect an increased number of somatic
heteroplasmic mtDNA mutations in PBMC after chemotherapy
(data not shown). Further evaluation of disease history and
treatment revealed that the ALL patient described above had
received a platelet concentrate 3 days prior to sampling of the
patients blood. Unfortunately, at that time point, the patient was
not available for additional investigations.
To test our hypothesis, that donor platelet contamination
might have mimicked the induction of heteroplasmic mtDNA
mutations in our patient, we investigated mtDNA mutations of
PBMCs of patients prior and after single donor platelet infusion.
White blood cells were isolated by selective lysis of red blood
Figure 1 MtDNA analysis of a patient prior and post-infusion of
platelets of a single donor. The first blood sample was collected at the
same day before the transfusion of the platelet-concentrate, the second
1 h after the transfusion and a third blood sample was collected 2
weeks later. Samples from patients were collected after informed
consent was given. Two regions of the mtDNA, containing parts of the
COI (6747–7088) gene and D-loop (16098–16456), were amplified
and sequenced as previously reported.7Sequence analysis of the first
PCR fragment (a–d) showed a 7028T variation in the blood sample
before the transfusion (a), and a 7028C variation in the donor platelets
(b). The blood sample drawn 1 h after the injection represents both
variants at 7028 (c). Sequence analysis of the second PCR fragment of
the patients blood sample before the injection showed 16213G,
16273C, 16294T, 16296T and 16304C, and the donor platelets
16213A, 16273T, 16294C, 16296C and 16304T. Only the last three
mutations are shown in the sequence (e–h). The blood sample drawn
1 h after the injection presented with the following mixtures 16213G/A,
16273C/T, 16294T/C, 16296T/C and 16304C/T (g). After 20 days, the
sequence variants of the donor mtDNA disappeared (d, h).
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cells and digested with proteinase K before PCR amplification.
DHPLC analysis and sequencing of the mtDNA revealed
heteroplasmy of patient blood DNA preparation due to the
presence of donor DNA of contaminating platelets (Figure 1). In
agreement with a recent study, we observed that even the
enrichment of PBMC by Ficoll Paques (Pharmacia Biotech,
Uppsala, Sweden) gradient did not substantially eliminate the
donor platelet contamination.6
Full clearance of donor mtDNA was observed after 3 weeks
(Figure 1).
The degree of heteroplasmy we noticed after platelet infusion
(30–70%) (Figure 1) was similar to that detected in most patients
in the study of Carew et al.5 Since platelet counts are frequently
low in CLL patients repeated platelet transfusions are necessary.
The untreated group of patients in the previous study had an
average lower disease stage and therefore might not have
received platelets within 3 weeks prior to sampling. In contrast,
toxicity of chemotherapy leads frequently to thrombocytopenia
and subsequent treatment with platelet concentrates.
There is no indication in the previous paper that patients
with prior platelet infusions were excluded from the study or if
the blood samples were taken at a certain interval after the end
of therapy or platelet infusion. However, the very high
frequency of high level heteroplasmic mutations in some of
the treated patients, as well as the almost identical picture
we obtained after sequence analysis of patients following
platelet infusion, led us to the conclusion that this is rather
caused by donor platelets and unlikely the consequence of
chemotherapy.
Determination of mtDNA mutations can only be reliably
performed at least 3 weeks after administration of blood
products to avoid detection of donor mtDNA. Alternatively, a
recently described procedure using special conditions for blood
collection to eliminate disturbing platelets could be employed
for isolation of PBMC.6
The high level of heteroplasmy observed by Carew et al.
could be explained by selective advantage. However, we would
not expect that in one patient, 12 distinct mutations can have a
selective advantage leading to similar high levels of hetero-
plasmy. Especially for synonymous heteroplasmic mutations a
selective pressure is most unlikely.
Epidemiological and geographic differences between indivi-
duals complicate the statistical interpretation of mtDNA
mutations if they are compared to the Cambridge reference
sequence. Therefore, analysis of therapy-induced mtDNA
mutations should be carried out on matched patients samples.
Ideally, buccal swabs, urine sediment or normal leucocytes
isolated by FACS sorting before initiation of therapy would be
the most appropriate reference material for screening of
chemotherapy-induced mtDNA mutations.
In conclusion, analysis of mtDNA mutations in peripheral
blood samples from patients with a recent history of donor
platelet transfusion should be interpreted consciously.
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The TEL-AML1 (ETV6-RUNX1) fusion is the most common
genetic alteration in childhood acute lymphoblastic leukemia
(ALL).1,2 Lines of evidence demonstrated the prenatal origins
of TEL-AML1 and the requirement of additional complementary
genetic events leading to overt leukemia.3,4 Ford et al 5 and
Konrad et al6 recently demonstrated that TEL-AML1-positive ALL
cells in late relapse were derived from a preleukemic clone not
eliminated by initial chemotherapy, suggesting that additional
molecular events within the common preleukemic clone give
rise to a new leukemia as a conventional relapse. A recent report
from Austrian BFM cooperative study group revealed that
duplication of TEL-AML1 was observed in approximately 15%
of TEL-AML1-positive ALL cases as one of the secondary genetic
abnormalities.7 However, it remains uncertain whether or not
duplication of TEL-AML1 is sufficient to generate overt
leukemia. To clarify this point, the clonotypic analysis of late
relapsed cases with double TEL-AML1 fusion would be
informative.
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